References
- Dal PanGJOngoing challenges in pharmacovigilanceDrug Safety20143711824264884
- HazellLShakirSAUnder-reporting of adverse drug reactions: a systematic reviewDrug Safety200629538539616689555
- US Food and Drug AdministrationGood Pharmacovigilance Practices and Pharmacoepidemiologic Assessment2005 Available from: https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdfAccessed April 2017
- Dal PanGJLindquistMGelperinKPostmarketing Spontaneous Pharmacovigilance Reporting SystemsStromBLKimmelSEHennessySTextbook of PharmacoepidemiologyChichesterJohn Wiley & Sons Ltd2013137158
- DaoRLSuSCChungWHRecent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanismsAsia Pac Allergy201552596725938070
- StruckMFHilbertPMockenhauptMReicheltBSteenMSevere cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromesIntensive Care Med2010361223219787334
- HarrTFrenchLEToxic epidermal necrolysis and Stevens-Johnson syndromeOrphanet J Rare Dis201053921162721
- HalevySGhislainPDMockenhauptMEuroSCAR Study GroupAllopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJ Am Acad Dermatol2008581253217919772
- Lamictal [webpage on the internet]SurryeMC [updated March 20, 2017]. Available from: http://www.medicines.org.uk/emc/medicine/4228Accessed June 20, 2017
- Phenobarbital Actavis Tablets BP 30 mg [webpage on the Internet]SurryeMC [updated December 30, 2013]. Available from: https://www.medicines.org.uk/emc/medicine/24077Accessed August, 2016
- Phenytoin Sodium Flynn Hard Capsules 25 mg, 50 mg, 100 mg and 300 mg [webpage on the internet]SurryeMC [updated November 9, 2016]. Available from: https://www.medicines.org.uk/emc/medicine/28811Accessed June 20, 2017
- LeviNBastuji-GarinSMockenhauptMMedications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysisPediatrics20091232e297e30419153164
- MockenhauptMViboudCDunantAStevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-studyJ Invest Dermatol20081281354417805350
- GubermanAHBesagFMBrodieMJLamotrigine-associated rash: risk/benefit considerations in adults and childrenEpilepsia199940798599110403224
- WangXQLvBWangHFLamotrigine-induced severe cutaneous adverse reaction: update data from 1999–2014J Clin Neurosci20152261005101125913750
- SeoHJChiesaALeeSJSafety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implicationsClin Neuropharmacol2011341394721242744
- Pharmaceuticals and Medical Devices AgencyDear Healthcare Professionals Letter of Rapid Safety Communication (Blue Letter), Serious Skin Disorders Suggestively Caused by Lamictal (Lamotrigine) Tablets2015 Available from: http://www.pmda.go.jp/files/000198527.pdfAccessed April 2016
- meddra.org [homepage on the Internet]Medical Dictionary for Regulatory Activities Available from: http://www.meddra.org/Accessed June 18, 2017
- MozzicatoPStandardised MedDRA queries: their role in signal detectionDrug Safety200730761761917604415
- Medical Dictionary for Regulatory Activities [webpage on the Internet]Standardised MedDRA Queries2016 Available from: http://www.meddra.org/standardised-meddra-queriesAccessed December 2016
- GlaxoSmithKlineLamictal US Prescribing Information2016 Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDFAccessed June 20, 2017
- Pharmaceuticals and Medical Devices AgencyPharmaceuticals and Medical Devices Safety Information, No. 321 March 20152015 Available from: https://www.pmda.go.jp/files/000205168.pdfAccessed April 2016